2. Academic Validation
  3. Ceritinib-a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer

Ceritinib-a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer

  • Transl Lung Cancer Res. 2014 Dec;3(6):379-81. doi: 10.3978/j.issn.2218-6751.2014.11.09.
Sacha I Rothschild 1
Affiliations

Affiliation

  • 1 Department Internal Medicine, Medical Oncology, University Hospital Basel, Basel, Switzerland.
PMID: 25806326 DOI: 10.3978/j.issn.2218-6751.2014.11.09
Figures
Products